Hepatocyte transplantation for liver-based metabolic disorders
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Hepatocyte transplantation is being investigated as an alternative to orthotopic liver transplantation in patients with liver-based metabolic disorders. The progress made in this field to date is reviewed. Protocols have been developed using collagenase perfusion to isolate human hepatocytes from unused donor liver tissue. Hepatocytes with a high viability can often be obtained and can be cryopreserved for later use, though with loss of function on thawing. For clinical use, hepatocytes must be prepared in clean GMP conditions with cells meeting criteria of function and lack of microbial contamination before patient use. Hepatocytes are infused intraportally into the patient's liver, where a proportion of cells will engraft and replace the deficient metabolic function without the need for major surgery. Twenty patients have now received hepatocyte transplantation, including eight children at King's College Hospital. There was a range of aetiologies of liver disease: familial hypercholesterolaemia, Crigler–Najjar syndrome type 1, urea cycle defects, infantile Refsum disease, glycogen storage disease type Ia, inherited factor VII deficiency and progressive familial intrahepatic cholestasis type 2. Clinical improvement and partial correction of the metabolic abnormality was observed in most cases. Considerable progress has been made in developing the technique, but hepatocyte transplantation is limited by the available supply of liver tissue. Hepatocytes derived from stem cells could provide alternative sources of cells in the future.
- Ambrosino G, Varotto S, Strom SC, et al (2005) Isolated hepatocyte transplantation for Crigler—Najjar syndrome type 1. Cell Transplant 14: 151–157.
- De Vree JM, Ottenhoff R, Bosma PJ, Smith AJ, Aten J, Oude Elferink RP (2000) Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 19: 1720–1730.
- Dhawan A, Mitry RR, Hughes RD, et al (2004) Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 78: 1812–1814. CrossRef
- Diener B, Utesch D, Beer N, Durk H, Oesch F (1993) A method for the cryopreservation of liver parenchymal cells for studies of xenobiotics. Cryobiology 30: 116–127. CrossRef
- Fausto N (2004) Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 39: 1477–1478. CrossRef
- Fox IJ, Roy-Chowdhury J (2004a) Hepatocyte transplantation. J Hepatol 40: 878–886. CrossRef
- Fox IJ, Chowdhury JR (2004b) Hepatocyte transplantation. Am J Transplant 4(Supplement 6): 7–13. CrossRef
- Fox IJ, Chowdhury JR, Kaufman SS, et al (1998) Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 338: 1422–1426. CrossRef
- Grossman M, Rader DJ, Muller DW, et al (1995) A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Medicine 1: 1148–1154. CrossRef
- Horslen SP, Fox IJ (2004) Hepatocyte transplantation. Transplantation 77: 1481–1486. CrossRef
- Horslen SP, McCowan TC, Goertzen TC, et al (2003) Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 111: 1262–1267. CrossRef
- Mitry RR, Hughes RD, Dhawan A (2002) Progress in human hepatocytes: isolation, culture and cryopreservation. Semin Cell Dev Biol 13: 463–467. CrossRef
- Mitry RR, Hughes RD, Aw MM, et al (2003) Human hepatocyte isolation and relationship of cell viability to early graft function. Cell Transplant 12: 69–74.
- Mitry RR, Dhawan A, Hughes RD, et al (2004) One liver, three recipients—segment IV from split liver procedures as a source of hepatocytes for cell transplantation. Transplantation 77: 1614–1616. CrossRef
- Muraca M, Gerunda G, Neri D, et al (2002) Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 359: 317–318. CrossRef
- Pereira SP, McCarthy M, Ellis AJ, et al (1997) Auxiliary partial orthotopic liver transplantation for acute liver failure. J Hepatol 26:1010–1017. CrossRef
- Sokal EM, Smets F, Bourgois A, et al (2003) Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation 76: 735–738. CrossRef
- Stephenne X, Najimi M, Smets F, Reding R, de Ville de Goyet J, Sokal EM (2005) Cryopreserved liver cell transplantation controls ornithine transcarbamylase deficient patient while awaiting liver transplantation. Am J Transplant 5: 2058–2061. CrossRef
- Strom SC, Fisher RA, Rubinstein WS, et al (1997) Transplantation of human hepatocytes. Transplant Proc 29: 2103–2106. CrossRef
- Strom SC, Dorko K, Thompson MT, Pisarov LA, Nussler AK (1998) Large scale isolation and culture of human hepatocytes. In: Franco D, Boudjema K, Varet B, eds. Îlots de Langerhans et hépatocytes. Paris: Les Editions INSERM, 195.
- Strom SC, Chowdhury JR, Fox IJ (1999) Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis 19: 39–48. CrossRef
- Terry C, Dhawan A, Mitry RR, Lehec SC, Hughes RD (2006) Pre-incubation of rat and human hepatocytes with cytoprotectants prior to cryopreservation can improve viability and function on thawing. Liver Transplant 12: 165–177. CrossRef
- Thompson R, Strautnieks S (2001) BSEP: function and role in progressive familial intrahepatic cholestasis. Semin Liver Dis 21: 545–550. CrossRef
- Hepatocyte transplantation for liver-based metabolic disorders
Journal of Inherited Metabolic Disease
Volume 29, Issue 2-3 , pp 431-435
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- Industry Sectors